We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$9.63B
AUM Growth
+$514M
Cap. Flow
-$223M
Cap. Flow %
-2.32%
Top 10 Hldgs %
52.93%
Holding
102
New
30
Increased
20
Reduced
19
Closed
21

Top Buys

Rank Stock Value
1
AABA
Altaba Inc
AABA
+$676M
2
BCR
CR Bard Inc.
BCR
+$435M
3
MBLY
Mobileye N.V.
MBLY
+$254M
4
NXPI icon
NXP Semiconductors
NXPI
+$163M
5
HUN icon
Huntsman Corp
HUN
+$134M

Top Sells

Rank Stock Value
1
YHOO
Yahoo Inc
YHOO
+$463M
2
BEAV
B/E Aerospace Inc
BEAV
+$322M
3
MJN
Mead Johnson Nutrition Company
MJN
+$319M
4
WWAV
The WhiteWave Foods Company
WWAV
+$205M
5
LLY icon
Eli Lilly
LLY
+$134M

Sector Composition

Rank Sector Weight
1 Technology 25.12%
2 Communication Services 21.97%
3 Healthcare 21.74%
4 Industrials 5.76%
5 Consumer Discretionary 4.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRFS
51
Grifois
GRFS
$5.44B
$22.8M 0.24%
1,079,874
– –
AKAO
52
DELISTED
Achaogen Inc
AKAO
$20.6M 0.21%
948,500
+131,000
+16% +$2.99M
AZN icon
53
AstraZeneca
AZN
$257B
$19.6M 0.2%
287,500
-288,750
-50% -$18.9M
PBYI icon
54
Puma Biotechnology
PBYI
$477M
$18.6M 0.19%
213,000
-367,500
-63% -$20.6M
SHPG
55
DELISTED
Shire pic
SHPG
$17.9M 0.19%
+108,500
New +$19M
NVET
56
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$17.7M 0.18%
2,648,696
– –
ALNY icon
57
Alnylam Pharmaceuticals
ALNY
$31.6B
$16M 0.17%
+200,000
New +$12.8M
H icon
58
Hyatt Hotels
H
$17B
$14.9M 0.15%
265,000
-349,000
-57% -$19.8M
PTLA
59
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$14M 0.15%
+250,000
New +$10M
SVRA icon
60
Savara
SVRA
$1.15B
$13.1M 0.14%
+2,225,000
New +$15.3M
RXDX
61
DELISTED
Ignyta, Inc.
RXDX
$11.9M 0.12%
+1,153,500
New +$9.37M
STML
62
DELISTED
Stemline Therapeutics, Inc.
STML
$10.6M 0.11%
1,157,500
-10,000
-0.9% -$83.4K
AKBA icon
63
Akebia Therapeutics
AKBA
$251M
$10.5M 0.11%
+730,000
New +$9.25M
WGL
64
DELISTED
Wgl Holdings
WGL
$10M 0.1%
+120,000
New +$9.95M
KATE
65
DELISTED
Kate Spade & Company
KATE
$9.8M 0.1%
530,000
+320,000
+152% +$5.9M
TGNA
66
DELISTED
TEGNA Inc
TGNA
$9.65M 0.1%
+670,000
New +$10.3M
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.84M 0.09%
745,000
-1,650,000
-69% -$20.5M
SAGE
68
DELISTED
Sage Therapeutics
SAGE
$7.96M 0.08%
+100,000
New +$7.23M
CYOU
69
DELISTED
Changyou.com Limited American Depositary Share
CYOU
$6.23M 0.06%
+160,812
New +$5.52M
AMRN
70
Amarin Corp
AMRN
$298M
$6.03M 0.06%
74,750
– –
PCO
71
DELISTED
Pendrell Corporation - Class A
PCO
$5.94M 0.06%
8,211
– –
BKD icon
72
Brookdale Senior Living
BKD
$2.82B
$4.85M 0.05%
+330,000
New +$4.56M
QCOM icon
73
Qualcomm
QCOM
$169B
$4.69M 0.05%
+85,000
New +$4.75M
IMGN
74
DELISTED
Immunogen Inc
IMGN
$3.59M 0.04%
+505,000
New +$2.31M
GCVRZ
75
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$2.6M 0.03%
6,827,805
– –
1 2
3
4

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2017 Portfolio in Review

As of Q2 2017, Thomas Steyer held 102 positions worth $9.63B, up 5.6% from $9.11B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Thomas Steyer's Q2 2017 filing shows 30 new, 20 increased, 19 reduced and 21 closed positions. Its largest new stake was Altaba Inc: 12,427,457 shares worth $677M. The largest sale was Yahoo Inc, an estimated $463M.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 15% a quarter earlier, followed by Communication Services and Healthcare.

  • Thomas Steyer's largest Q2 2017 buy was Altaba Inc: 12,427,457 shares worth $677M.
  • Thomas Steyer added most to Mobileye N.V. in Q2 2017, an estimated $254M increase.
  • Thomas Steyer's biggest Q2 2017 reduction was Allergan plc, cutting an estimated $98.7M.
  • Thomas Steyer fully exited Yahoo Inc in Q2 2017, selling an estimated $463M.
  • Thomas Steyer's ten largest holdings make up 53% of its $9.63B portfolio in Q2 2017.
  • Thomas Steyer opened 30 new positions and closed 21 in Q2 2017.
  • Thomas Steyer's portfolio value rose 5.6% quarter-over-quarter to $9.63B.

Based on Farallon Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.